Xigen S.A., a Swiss biotechnology company engaged in research and development of intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer, announced the appointment of Didier Coquoz, Pharm. D., Ph.D. as Chief Executive Officer. Dr. Coquoz was most recently Vice-President Research and Development of H3 Pharma in Montreal, Canada.
